Brief: PCI Biotech Holding Q4 Operating Loss Narrows To NOK 21.4 Mln
Feb 24 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* REG-PCI BIOTECH FOURTH QUARTER AND PRELIMINARY FULL YEAR
2020
RESULTS
* Q4 OPERATING LOSS NOK 21.4 MILLION VERSUS LOSS NOK 25.3
MILLION
YEAR AGO
* EXPECTED TIMELINE FOR PLANNED INTERIM ANALYSIS OF RELEASE
STUDY
REMAINS IN RANGE FROM 2H 2022 TO 1H 2023
Source text for Eikon: ID:nGNE531MLW
Further company coverage: PCIB.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process